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OBJECTIVEdWe evaluated the safety and efﬁcacy of closed-loop basal insulin delivery dur-
ing sleep and after regular meals and unannounced periods of exercise.
RESEARCH DESIGN ANDMETHODSdTwelve adolescents with type 1 diabetes (ﬁve
males; mean age 15.0 [SD 1.4] years; HbA1c 7.9 [0.7]%; BMI 21.4 [2.6] kg/m
2) were studied at a
clinical research facility on two occasions and received, in random order, either closed-loop basal
insulin delivery or conventional pump therapy for 36 h. During closed-loop insulin delivery,
pump basal rates were adjusted every 15 min according to a model predictive control algorithm
informed by subcutaneous sensor glucose levels. During control visits, subjects’ standard in-
fusion rates were applied. Prandial insulin boluses were given before main meals (50–80 g
carbohydrates) but not before snacks (15–30 g carbohydrates). Subjects undertook moderate-
intensity exercise, not announced to the algorithm, on a stationary bicycle at a 140 bpm heart rate
in the morning (40 min) and afternoon (20 min). Primary outcome was time when plasma
glucose was in the target range (71–180 mg/dL).
RESULTSdClosed-loop basal insulin delivery increased percentage time when glucose was in
the target range (median 84% [interquartile range 78–88%] vs. 49% [26–79%], P = 0.02) and
reduced mean plasma glucose levels (128 [19] vs. 165 [55] mg/dL, P = 0.02). Plasma glucose
levels were in the target range 100% of the time on 17 of 24 nights during closed-loop insulin
delivery. Hypoglycemia occurred on 10 occasions during control visits and 9 occasions during
closed-loop delivery (5 episodes were exercise related, and 4 occurred within 2.5 h of prandial
bolus).
CONCLUSIONSdDay-and-night closed-loop basal insulin delivery can improve glucose
control in adolescents. However, unannounced moderate-intensity exercise and excessive pran-
dial boluses pose challenges to hypoglycemia-free closed-loop basal insulin delivery.
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C losed-loop insulin delivery is anemerging technology that may trans-form management of type 1 diabetes
(1). Coupling subcutaneous continuous
glucose monitoring (2,3) and insulin
pump delivery (4), the closed-loop tech-
nology delivers insulin in a continually
glucose-responsive fashion to reduce the
risk of hypoglycemia and to improve over-
all glucose control (5,6).
This novel approach differs from
conventional pump therapy through the
use of a control algorithm that directs
subcutaneous insulin delivery according
to subcutaneous sensor glucose levels (7).
Previous randomized studies with an
adaptive algorithm controlling basal insu-
lin demonstrated effectiveness of closed
loop during sleep (8,9). Application
after a standard evening meal and late-
afternoon exercise resulted in a 20%
improvement in the number of glucose
levels overnight within the target range
while reducing the risk of nocturnal hy-
poglycemia in children and adolescents
(8). Similar improvements were observed
in adults after a standard dinner and a
large evening meal accompanied by alco-
hol (9). Feasibility of closed-loop control
has also been explored in pregnancy
(10,11). The future challenge is to deter-
mine whether closed-loop insulin deliv-
ery can maintain glycemic control after
meals, physical exercise, and snacks,
where to date, published studies have
been encouraging but have lacked a con-
ventional therapy comparator (12,13).
Meals and physical activity cause
rapid ﬂuctuations in blood glucose levels,
which challenge the closed-loop ap-
proach because of delays associated with
the subcutaneous route of insulin delivery
and glucose sensing errors. We addressed
this question by evaluating closed-loop
basal insulin delivery systems with
proven efﬁcacy overnight during a 36-h
period that comprised waking hours and
common daily activities, including a typ-
ical school day, and behaviors of adoles-
cents.
RESEARCH DESIGN AND
METHODSdWe carried out an open-
label, randomized controlled crossover
study to compare closed-loop basal in-
sulin delivery and conventional pump
therapy in adolescents with type 1 di-
abetes. The study aimed to replicate
common daily activities during two 36-h
study periods, each comprising 2 nights
and 1 day.
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O R I G I N A L A R T I C L E
The study was approved by the
Southampton and South West Hamp-
shire Research Ethics Committee B. Par-
ticipants ,16 years of age provided
assent to the study procedures, and in-
formed consent was signed by the parent
or caregiver. Subjects $16 years of age
signed their own consent before partici-
pation.
Setting and subjects
The study was conducted at the Well-
come Trust Clinical Research Facility at
Addenbrooke’s Hospital (Cambridge,
U.K.) between March and November
2010. Young people aged 12–18 years
from 3 pediatric diabetes clinics at
Cambridge University Hospital, London
and Norwich, took part. Inclusion criteria
were type 1 diabetes (World Health Orga-
nization criteria), duration of at least 1
year, and insulin pump therapy for at least
3 months. C-peptide level was not mea-
sured. Adolescents with poor glycemic
control (HbA1c .12% [108 mmol/mol])
and signiﬁcant insulin resistance (total
daily dose .2 units/kg/day) were ex-
cluded. Additional exclusion criteria
were clinically signiﬁcant nephropathy
or retinopathy and hypoglycemia un-
awareness. Subjects used an insulin bolus
calculator to titrate prandial insulin bo-
luses. Insulin-to-carbohydrate ratios and
insulin sensitivity factors were determined
in collaboration with treating clinicians.
Supplementary Fig. 1 shows the ﬂow of
participants through the study.
Study design
Subjects attended the clinical research
facility on two occasions and underwent
closed-loop basal insulin delivery and
conventional pump therapy in random
order. The visits were separated by an
interval of 1–6 weeks, during which con-
tinuous glucose monitoring was discon-
tinued and subjects continued their
standard insulin pump therapy and diet
regimen.
Study procedures
Continuous glucose monitoring was es-
tablished 24–48 h before each study visit
by inserting a single subcutaneous glu-
cose sensor (SEVEN PLUS; Dexcom, Inc;
San Diego, CA) into the subcutaneous
tissue of the abdomen. Calibration fol-
lowed manufacturer’s instructions, which
included ﬁnger-stick glucose measure-
ments taken every 12 h using the subject’s
own glucosemeter checked for accuracy by
calibration ﬂuid.
On each occasion, subjects were ad-
mitted at 1730 h on day 1 and stayed until
0800 h on day 3. On arrival, the subject’s
insulin pump was replaced with a study
pump (Animas 2020; Johnson & Johnson,
Lititz, PA) connected to the existing infu-
sion site and infusing the rapid-acting in-
sulin analog aspart (Novo Nordisk,
Bagsværd, Denmark). An intravenous can-
nula was inserted into an antecubital vein
and kept patent with saline to allow for
frequent blood sampling starting at 1830
h on day 1.
Meals and activities
The subjects consumed self-selected
meals and snacks fromstandardizedmenus
that were identical on the two study
visits. Meals (breakfast 50 g carbohydrates
at 0800 h, lunch 70 g at 1300 h, and
dinner 80 g at 1900 h) were accompanied
by insulin boluses calculated using the
subjects’ standard insulin pump bolus cal-
culator settings. Meal boluses included
correction according to premeal ﬁnger-
stick glucose levels. At a ﬁnger-stick value
of #72 mg/dL, boluses were given with
the meal; otherwise, they were given 10
min before the meal. Snacks containing
15 g carbohydrates were given in the even-
ing at 2100 h on day 1 and day 2 and in the
morning at 1015 h on day 2. An afternoon
snack of 30 g carbohydrates was con-
sumed at 1600 h on day 2. No insulin
boluses were given before these snacks
during either the conventional pump ther-
apy or the closed-loop basal insulin deliv-
ery. Subjects were discouraged from
taking additional ﬁnger-stick mea-
surements between meals. Hypoglycemia
was treated with oral carbohydrates (15–
30 g in drink), adopting an identical pro-
tocol in the two treatment arms.
Subjects engaged in physical activity
consisting of two 20-min walks outside
the clinical research facility within the
hospital campus at 0840 and 1530 h on
day 2 and two structured, moderate-
intensity exercise sessions on a stationary
bicycle at a heart rate of 140 bpm. The
latter included a morning session of 40
min duration at 1040 h and a 20-min
session in the afternoon at 1730 h. Sub-
jects engaged in other common daily
activities, such as playing computer
games, reading, and watching television.
Physical activity energy expenditure
(PAEE) was evaluated by an Actiheart mon-
itor (CamNtech Ltd, Cambridge, U.K.)
measuring combined heart rate and accel-
eration (14,15) to ensure comparable activ-
ity on the two occasions. Subjects were
ﬁtted with the Actiheart monitor on arrival.
Themonitor was calibrated using an 8-min
step test (16). After the end of theﬁrst study
visit, subjects wore the Actiheart monitor
for an additional 36–72 h to evaluate PAEE
in the home setting between study visits.
Closed-loop basal insulin delivery
An algorithm based on model predictive
control (7) was used to alter basal insulin
delivery during closed-loop visits. From
1930 h on day 1 and every 15 min, a re-
search nurse initiated a control cycle. The
nurse inputted the sensor glucose value
into the computer-based algorithm, the
algorithm calculated the basal infusion
rate, and the nurse adjusted the insulin
pump accordingly. This procedure was
continued for 36 h. Prandial insulin bo-
luses were delivered according to the sub-
ject’s standard practice, using his or her
individual pump bolus calculator and
ﬁnger-stick glucose levels. The algorithm
was initialized using the subject’s weight,
total daily insulin dose (mean of previous
3 days), and 24-h basal insulin proﬁle as
programmed on the pump. Additionally,
the algorithm was provided with sensor
glucose levels measured during a 30-min
period preceding the start of closed-loop
delivery, the carbohydrate content of
main meals, and prandial insulin boluses.
Information on snacks and physical activ-
ity was not provided to the algorithm. The
algorithm adapted itself to a particular
subject by updating two model parame-
ters: 1) an endogenous glucose ﬂux cor-
recting for errors in model-based
predictions and 2) carbohydrate bioavail-
ability. Several competing models differing
in the absorption of subcutaneous insulin
and oral carbohydrates ran in parallel (17).
The algorithm aimed to achieve glucose
levels between 105 and 130 mg/dL and
adjusted the actual level depending on fast-
ing versus postprandial status and the ac-
curacy ofmodel-based glucose predictions.
Safety rules limited maximum insulin infu-
sion and suspended insulin delivery at a
sensor glucose level #75 mg/dL or when
the sensor glucose level was rapidly de-
creasing. Control algorithm versions
0.03.01–0.03.07were used (8,9). Only ini-
tialization parameterswere entered for each
subject; the principles of the control ap-
proach and the main algorithm parameters
remained unchanged across all versions
tested.
Sampling and assays
Venous blood samples were collected for
the measurement of glucose and insulin
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concentrations every 30 min during the
day and hourly overnight, but these were
not used to calculate insulin require-
ments. Additional venous samples were
taken every 15 min when plasma glucose
was#70 mg/dL. Plasma was immediately
separated by centrifugation. Plasma glu-
cose levels were determined in real time
by a YSI2300 STAT Plus analyzer (Yellow
Springs Instruments, Farnborough, U.K.)
but were not used to inform the algo-
rithm. Plasma insulin concentration was
measured by immunochemiluminomet-
ric assay (Invitron, Monmouth, U.K.) (in-
tra-assay coefﬁcient of variation 4.7%,
interassay coefﬁcient of variation 7.2–
8.1%). Insulin aspart demonstrated
100% cross-reactivity in this assay.
Sample size, randomization, and
masking
Based on previous data (8), we antici-
pated that closed-loop basal insulin deliv-
ery would increase the percentage of time
when plasma glucose levels would be
within the target range (71–180 mg/dL)
by 37 (40)%. We calculated that 12 sub-
jects would provide 80% power at the 5%
level of signiﬁcance to detect this differ-
ence compared with conventional insulin
pump therapy. After informed consent
and assent, the randomization procedure
used a computer-generated allocation se-
quence, with permuted blocks placed in
sealed envelopes. Investigators had access
to plasma glucose levels for safety reasons,
but subjects remained masked to plasma
and sensor glucose data.
Statistical analysis
Senior investigators and study statisti-
cians agreed on the analysis plan in
advance. The primary outcome was the
timewith plasma glucose levels within the
target range (71–180 mg/dL) over a 32-h
period from 2400 h on day 1 to 0800 h on
day 3. Secondary outcomes included
mean plasma glucose, time when glucose
concentration was #70 mg/dL (hypogly-
cemia), time when glucose concentration
was .180 mg/dL (hyperglycemia), time
with plasma glucose levels between 70
and 145 mg/dL overnight from 2400–
0800 h, mean rate of insulin infusion, and
mean plasma insulin concentrations. Low
blood glucose index was used to assessed
the duration and extent of hypoglycemia
and was calculated using transformed glu-
cose measurements that penalized progres-
sively low glucose levels (18).
Parents of one subject withdrew con-
sent; thus, the subject did not complete
the study and was excluded from the
analysis. For each outcome, a repeated-
measures regression model based on the
ranked normal transformation (except for
the mean glucose concentration, which
was not transformed because it already
had an approximate normal distribution)
was ﬁtted to compare the two treatments,
adjusting for plasma glucose level at the
start of closed-loop treatment and for
period effect. Analyses were conducted
with SAS version 9.2 (SAS Institute, Cary,
NC) statistical software. Outcomes were
calculated using time-weighted data by
GStat version 1.1.2 (University of Cam-
bridge, Cambridge, U.K.) software. Ker-
nel density of time-weighted plasma
glucose was estimated using the package
“nonparametric kernel smoothing meth-
ods for mixed data types” version 0.40-1,
adopting a bandwidth of 0.25 mmol/L
and implemented in the R version
2.11.1 (The R Foundation for Statistical
Computing). Results are presented as me-
dian (interquartile range) or mean (SD),
unless stated otherwise.
RESULTS
Participants
Twelve adolescents completed the study
(5 males, age 15.0 [1.4] years, HbA1c
7.9 [0.7]% [63 (16) mmol/mol], BMI
21.4 [2.6] kg/m2). Subjects’ baseline char-
acteristics are shown in Supplementary
Table 1.
Day-and-night glucose control
Plasma glucose, insulin delivery, and
plasma insulin during conventional in-
sulin pump therapy and closed-loop basal
insulin delivery are shown in Fig. 1.
When compared with standard pump
therapy, time when plasma glucose was
in the target range increased during
closed-loop basal insulin delivery from
49% (26–79%) to 84% (78–88%) (P =
0.02) (Table 1). The mean plasma glucose
concentration was signiﬁcantly reduced
from 165 (55) to 128 (20) mg/dL (P =
0.02). No difference was found in the
time spent in the hypoglycemic range
#70 mg/dL (P = 0.85) or the hyperglyce-
mic range .180 mg/dL (P = 0.15). How-
ever, closed-loop basal insulin delivery
reduced the time spent in hyperglycemia
.300 mg/dL (P = 0.03). Distribution of
plasma glucose levels over the 32-h evalu-
ation period during the 2 treatment periods
is illustrated in Supplementary Fig. 2.
Closed-loop basal insulin delivery
achieved consistent outcomes across all
subjects (Fig. 2). The range of mean
plasma glucose levels was considerably
tighter (107–161 vs. 85–258 mg/dL
closed-loop versus conventional pump
therapy, respectively). Similar observa-
tions applied to the time spent in the tar-
get range.
Insulin infusion rates, excluding
prandial insulin delivery, were higher
during closed-loop delivery (1.1 [0.9–
1.7] vs. 0.9 [0.7–1.4] units/h, P =
0.006), resulting in an increased overall
insulin delivery (P = 0.04) and reﬂected
by higher mean plasma insulin concentra-
tion (P = 0.02).
Table 2 separates outcomes during the
night (2400–0800 h) and day (0800–2400
h on day 2). Plasma glucose levels were in
the target range 100% of the time for 17 of
24 nights during closed-loop insulin deliv-
ery. Mean overnight glucose levels were
reducedduring closed-loop versus conven-
tional pump therapy. Time in target during
the day favored closed-loop basal insulin
delivery. Time spent in hypoglycemia was
comparable between these periods and
similar to the overall 32-h data. Insulin in-
fusion rateswere higher during closed-loop
delivery both during the day and during
the night and was associated with higher
plasma insulin concentrations at night but
not during the day. Study outcomes during
morning, afternoon, evening, and periods
of exercise are summarized in Supplemen-
tary Table 2 and Supplementary Fig. 3.
Sensor accuracy
The median relative absolute difference of
the Dexcom continuous glucose monitor
was 14.7% (7.0–25.3%). Clarke error grid
analysis (19) showed that 97.6% of the val-
ues were in zones A and B, 0.5% in zone C,
1.9% in zone D, and 0.1% in zone E.
Hypoglycemia
Timing and level of hypoglycemia are
illustrated in Fig. 1A. Ten episodes of
hypoglycemia ,55 mg/dL requiring
treatment were documented during con-
ventional insulin pump therapy and nine
during closed-loop basal insulin delivery.
One nocturnal hypoglycemic event oc-
curred during conventional therapy, and
none occurred during closed-loop deliv-
ery. All but one of the daytime episodes
during closed-loop basal insulin delivery
were associated with symptoms. During
closed-loop therapy, four hypoglycemia
events occurred within 2.5 h of breakfast
or dinner, and ﬁve episodes occurred after
exercise.
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Physical activity energy expenditure
Mean PAEE over 32 h from 2400 h on day
1 to 0800 h on day 3 was identical during
the two study visits (22 [7] kJ/kg/day)
(Supplementary Fig. 4). PAEE over a 24-h
period tended to be higher and more
variable at home than that during study
visits (38 [21] vs. 29 [9] kJ/kg).
CONCLUSIONSdWe present the
ﬁrst randomized study to our knowledge
reporting clinically signiﬁcant lowering of
mean plasma glucose over 32 h, suggest-
ing that day-and-night closed-loop basal
insulin delivery may improve glucose
control in adolescents with type 1 di-
abetes. Time in target $70% threshold
was recorded in all subjects during
closed-loop basal insulin delivery,
whereas during conventional pump ther-
apy, only one third of participants
presented a comparable outcome. If ex-
trapolated to long-term control, the im-
proved glucose levels could represent a
$1% fall in HbA1c (20).
Closed-loop basal insulin delivery
during the night was particularly beneﬁ-
cial. We observed a 100% time in target
for glucose levels during 17 of 24 nights.
Plasma glucose was 76–95%of the time in
the tighter glucose range from 71–145
mg/dL during the 2 study nights. This
compares well with our previous investi-
gations of overnight closed-loop insulin
delivery using a similar control algorithm
but different off-the-shelf glucose sensors
(8,9). Only on 3 of 24 nights were plasma
glucose levels #70 mg/dL. This level of
control was achieved because the algo-
rithm increased total overnight insulin
delivery after the evening snack, where
there was no accompanying insulin bolus,
and maintained glucose control through-
out the night.
During waking hours, beneﬁts of
closed-loop basal insulin delivery were
present but less pronounced possibly
because of the use of comparable ap-
proaches to prandial insulin delivery,
which normally constitutes ;50% of to-
tal daily insulin dose. Hyperglycemia
.300 mg/dL was reduced, conﬁrming
the ability of the closed-loop approach
to limit long periods of excessive glucose
levels. Prandial insulin boluses were
slightly reduced, and this likely results
from lower prebreakfast glucose levels
during closed-loop basal insulin delivery.
However daytime control was challenged
by moderate-intensity exercise and by
prandial insulin boluses calculated using
the standard insulin bolus calculator,
which although convenient, may have
limited accuracy. In three instances, pran-
dial insulin boluses were too large, possi-
bly as a result of acutely overestimated
insulin-to-carbohydrate ratios, and hypo-
glycemia occurred, despite reduction of
basal insulin delivery by 30, 60, or 100%
compared with the preprogrammed rate.
Preemptive reduction of prandial boluses
during closed-loop delivery could have
decreased the risk of postprandial hypogly-
cemia, but complete omission of prandial
Figure 1dPlasma glucose (A), insulin infusion rates (B), and plasma insulin (C) for conven-
tional insulin pump therapy and closed-loop basal insulin delivery (median [interquartile
range]). Meals (M), snacks (S), and exercise sessions are indicated. A: Episodes of hypoglycemia
requiring treatment (○, insulin pump therapy;C, closed-loop delivery).
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boluses as adopted by some fully closed-
loop approaches is unlikely to be sufﬁ-
ciently effective (12) given delays associated
with the absorption of rapid-acting ana-
logs (5). Supplementary Fig. 5 shows an
example of a hypoglycemic event that oc-
curred 2 h after the evening meal during
closed-loop therapy. The subject’s premeal
glucose level was 137 mg/dL; thus, 16 U
insulin was administered 10 min before a
meal of 80 g carbohydrates. Closed-loop
delivery started 30 min after the meal and
directed 0.08 U insulin over 90 min, com-
pared with 3.06 U that would have been
delivered during conventional treatment,
before hypoglycemia of 44mg/dL occurred
andwas treated by 30 g oral carbohydrates.
Insulin delivery was gradually reestab-
lished by closed-loop therapy 1 h after
the hypoglycemic episode was treated, al-
lowing euglycemia to be maintained over-
night.
We tried to reproduce a typical exer-
cise pattern, including walks, play during
school breaks, and after-school activities,
and did not announce these activities to
the control algorithm. We achieved com-
parable glucose control during and after
the moderate-intensity exercise on the
two study visits; however, it was associated
with hypoglycemia in some subjects.
Physical activity causes rapid changes in
insulin sensitivity (21), leading to glucose
drops of variable magnitude. On ﬁve occa-
sions, and particularly after the longer
morning exercise, the closed loop was un-
able to arrest despite reducing or fully sus-
pending insulin delivery. Unlike during
conventional pump therapy, snacks pre-
ceding exercise did not fully alleviate the
risk of hypoglycemia because the closed
loop responded by increasing insulin deliv-
ery before exercise. The main beneﬁts
of not announcing exercise are reduced
burden, ease of operation, and addressing
compliance and adherence concerns that
are pronounced in adolescents (22).
Reducing time between closed-loop adjust-
ments could accelerate recognition of an
exercise-related drop in sensor glucose
levels, but this is unlikely to be effective
given the extended action of already-de-
livered insulin. Announcement of exer-
cise to the algorithm at $30 min may
be required to achieve improved out-
comes and to reduce the risk of hypo-
glycemia.
Further challenges were related to the
magnitude and duration of sensor errors.
Overall accuracy expressed as the median
absolute relative difference did not differ
from that reported by the manufacturer
(14.7 vs. 13%) and by others (23). How-
ever, up to 5-h periods of sensor overes-
timation by $60 mg/dL were observed
and led to one postprandial hypoglycemic
episode. Sensor overreading is of particu-
lar concern because insulin overdelivery
may occur and increase the risk of hypo-
glycemia. Prolonged errors of large mag-
nitude occur infrequently, but computer
simulators, once appropriately validated
(24), may allow preclinical assessment
of safety of control algorithms under
such infrequent, but critical conditions
(25).
Previous studies reported by Steil
et al. (13) evaluated a fully automated
closed-loop system over a day-and-night
period but without physical activity and
snacks. Using a proportional integral de-
rivative algorithm, plasma glucose levels
were within the target range 75% of the
time. Postprandial hyperglycemia and de-
layed hypoglycemia were observed and
reduced in follow-up studies with the
use of small prandial priming insulin bo-
luses (12). Further modiﬁcations were
made to reduce insulin delivery at ele-
vated projected plasma insulin levels
(26). Alternative closed-loop approaches
include coadministration of glucagon to
Table 1dStudy outcomes over 32 h from 2400 h on day 1 to 0800 h on day 3 based on
plasma glucose levels
Outcome
Insulin pump
therapy (n = 12)
Closed-loop
delivery (n = 12) P
Primary outcome
Time in target of 71–180 mg/dL (%) 49 (26–79) 84 (78–88) 0.02
Secondary outcomes
Mean (SD) glucose (mg/dL) 165 (55) 128 (19) 0.02
SD of glucose (mg/dL) 48 (33–53) 36 (32–41) 0.09
Time in target of 71–145 mg/dL (%) 34 (20–58) 65 (57–75) 0.002
Hypoglycemia
#70 mg/dL (%) 3.8 (0.0–9.4) 4.5 (2.2–7.0) 0.85
#63 mg/dL (%) 2.3 (0.0–3.6) 2.2 (1.4–4.9) 0.66
Low blood glucose index 0.9 (0.2–1.5) 1.3 (0.6–2.0) 0.23
Hyperglycemia
.180 mg/dL (%) 40.1 (1.9–69.3) 9.6 (5.0–15.6) 0.15
.300 mg/dL (%) 0.0 (0.0–7.8) 0.0 (0.0–0.0) 0.03
Insulin infusion 0.9 (0.7–1.4) 1.1 (0.9–1.7) 0.006
Insulin concentration (pmol/L) 255 (226–279) 273 (231–316) 0.02
Insulin boluses (units) 24.5 (22.2–28.2) 21.2 (20.3–25.8) 0.04
Total insulin (units) 54.0 (46.8–72.9) 56.8 (51.8–78.7) 0.04
Data are median (interquartile range) unless otherwise indicated.
Figure 2dTimewhen plasma glucose levels are within the target range of 71–180mg/dL (A) and
mean plasma glucose levels (B) during conventional insulin therapy and closed-loop delivery.
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counteract delayed or excessive insulin
action (27–29). Practical limitations asso-
ciated with dual infusion apply.
The novelty of the present work is in
testing closed-loop basal insulin delivery
during common daily activities, including
moderate-intensity exercise, eating
snacks not accompanied by insulin bo-
luses, and relying on a single sensor
calibrated according to the manufactur-
er’s instructions in preparation for home
testing. The study was designed to
replicate a typical school day of adoles-
cents who often eat snacks not accompa-
nied by insulin after school and then
engage in moderate physical activity,
such as playing outside or attending after-
school clubs. It could be argued that if
we accompanied snacks with insulin
boluses, we could cause additional hypo-
glycemia after early evening exercise,
causing a disadvantage to the conven-
tional treatment. Similar reasoning about
habitual behavior of adolescents applies
to evening snacks and concurs with re-
ports that missing insulin boluses is a
common occurrence in adolescents
(30,31) that disagrees with treatment
guidelines. Treatment guidelines are difﬁ-
cult to impose in this particular age group
and the result is prolonged hyperglycemia,
as observed in the current study. Future
study designs may consider whether even-
ing snacks may be omitted during closed-
loop basal insulin delivery given that the
risk of nocturnal hypoglycemia is miti-
gated through insulin-responsive insulin
delivery. Asymmetric study designs may
be more reﬂective of anticipated clinical
use of closed-loop systems than of conven-
tional pump therapy.
Subjects were representative of a typ-
ical population of adolescents with type 1
diabetes. They were recruited from three
nationally leading pediatric diabetes clin-
ics, and their conventional treatment, not
optimized for the purposes of this study,
reﬂected typical glucose control that
served as an adequate comparator to
access beneﬁts of closed-loop basal insu-
lin delivery. This is further strengthened
by a comparable HbA1C (7.9 vs. 7.9%)
and time in target range (48 vs. 47%) in
adolescents/young adults at baseline of
the JDRF Continuous Glucose Monitor-
ing study (32).
We demonstrated that despite peri-
ods of suboptimal sensor accuracy,
closed-loop basal insulin delivery may
improve glucose control without increas-
ing the risk of hypoglycemia. The draw-
backs are that we were not able to prevent
hypoglycemia during waking hours and
that physical activity did not fully repro-
duce home patterns characterized by a
higher mean and higher variability of
energy expenditure. An additional draw-
back is that basal insulin delivery rates
were changed manually and automation,
though technologically feasible, was not
used.
In conclusion, day-and-night closed-
loop basal insulin delivery using off-the-
shelf devices and an adaptive control
algorithm may improve glycemic control
in adolescents with type 1 diabetes.
Unannounced moderate-intensity exer-
cise and prandial insulin overdosing
pose challenges to hypoglycemia-free
closed-loop basal insulin delivery.
Closed-loop systems may represent a tan-
gible treatment option for young people
with type 1 diabetes, improving glucose
control during adolescence.
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First night Daytime Second night
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delivery (n = 12)
Insulin pump
therapy (n = 12)
Closed-loop
delivery (n = 12)
Insulin pump
therapy (n = 12)
Closed-loop
delivery (n = 12)
Time in target of 71–180 mg/dL (%) 56 (12–85) 100 (96–100) 54 (37–81) 70 (65–79) 42 (0–85) 100 (99–100)
Mean (SD) glucose (mg/dL) 170 (71) 124 (22) 155 (49) 136 (22) 180 (69) 118 (25)
SD of glucose (mg/dL) 22 (13–30) 17 (13–19) 53 (35–60) 44 (38–48) 21 (14–36) 17 (10–20)
Time in target of 71–145 mg/dL (%) 28 (0–54) 76 (52–95) 47 (24–53) 52 (38–60) 26 (0–67) 95 (59–99)
Hypoglycemia
#70 mg/dL (%) 0.0 (0.0–0.4) 0.0 (0.0–0.0) 7.5 (0.0–12.3) 8.9 (4.4–11.9) 0.0 (0.0–9.9) 0.0 (0.0–0.0)
#63 mg/dL (%) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 3.5 (0.0–7.2) 4.4 (2.8–8.2) 0.0 (0.0–2.2) 0.0 (0.0–0.0)
Low blood glucose index 0.0 (0.0–0.5) 0.2 (0.0–0.8) 1.6 (0.3–2.3) 2.0 (0.9–2.6) 0.0 (0.0–1.5) 0.4 (0.1–1.2)
Hyperglycemia
.180 mg/dL (%) 35.0 (0.0–88.4) 0.0 (0.0–0.0) 31.2 (3.7–55.9) 18.5 (9.9–24.9) 49.9 (0.0–100.0) 0.0 (0.0–0.0)
.300 mg/dL (%) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–11.8) 0.0 (0.0–0.0) 0.0 (0.0–2.3) 0.0 (0.0–0.0)
Insulin infusion (units/h) 0.9 (0.8–1.1) 1.3 (0.8–1.7) 0.9 (0.7–1.6) 1.1 (0.8–1.8) 0.9 (0.8–1.1) 1.1 (0.9–1.4)
Insulin concentration (pmol/L) 170 (140–195) 228 (157–282) 336 (297–367) 323 (289–405) 171 (142–218) 205 (164–249)
Data are median (interquartile range) unless otherwise indicated. Daytime is deﬁned as 0800–2400 h on day 2 and nighttime as 2400 h on day 1 to 0800 h on day 2 for
the ﬁrst night and 2400 h on day 2 to 0800 h on day 3 for the second night.
care.diabetesjournals.org DIABETES CARE, VOLUME 36, APRIL 2013 843
Elleri and Associates
D.E. and J.M.A. were responsible for
screening and enrollment of subjects and
arranged informed consent from the subjects.
D.E., J.M.A., K.K., L.L., and K.C. provided
patient care, collected the clinical and labora-
tory data, and contributed to biochemical
analysis. D.E., J.M.A., H.R.M.,M.E.W., C.L.A.,
D.B.D., and R.H. designed the studies. D.E.,
M.N., P.C., C.K., A.H., and R.H. carried out or
supported the data analysis, including the sta-
tistical analyses. D.E., H.R.M., C.L.A., D.B.D.,
and R.H. contributed to the interpretation of the
results and the writing and critical review of the
manuscript. M.E.W. carried out randomization.
R.H. coordinated the study and designed
and implemented the glucose controller. D.E.
and R.H. are the guarantors of this work and, as
such, had full access to all the data in the study
and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Parts of this studywere presented in abstract
form at the 71st Scientiﬁc Sessions of the
American Diabetes Association, San Diego,
California, 24–28 June 2011.
The authors thank the study volunteers for
their participation and the staff members of the
Wellcome Trust Clinical Research Facility for
their help in conducting the studies. Ulf Eke-
lund, MRC Epidemiology Unit, Cambridge,
and collaborators processed the Actiheart data.
Nandu Thalange, Norfolk and Norwich Uni-
versity Hospital, and Peter Hindmarsh, Uni-
versity College, London, helped to identify
potential recruits. Josephine Hayes, Institute
of Metabolic Science, University of Cam-
bridge, provided administrative support.
Angie Watts, Department of Paediatrics, Uni-
versity of Cambridge, provided laboratory
support. Joanna Weston provided dietary
support. The Diabetes Research Network
Laboratory Wales (Steve Luzio) measured
plasma insulin.
References
1. Kowalski AJ. Can we really close the loop
and how soon? Accelerating the availability
of an artiﬁcial pancreas: a roadmap to better
diabetes outcomes. Diabetes Technol Ther
2009;11(Suppl 1):S113–S119
2. Klonoff DC. Continuous glucose monitor-
ing: roadmap for 21st century diabetes
therapy. Diabetes Care 2005;28:1231–1239
3. Hoeks LB, GrevenWL, de Valk HW. Real-
time continuous glucose monitoring sys-
tem for treatment of diabetes: a systematic
review. Diabet Med 2011;28:386–394
4. Pickup J, Keen H. Continuous sub-
cutaneous insulin infusion at 25 years:
evidence base for the expanding use of
insulin pump therapy in type 1 diabetes.
Diabetes Care 2002;25:593–598
5. Hovorka R. Closed-loop insulin delivery:
from bench to clinical practice. Nat Rev
Endocrinol 2011;7:385–395
6. Steil GM, Panteleon AE, Rebrin K. Closed-
loop insulindelivery-thepath tophysiological
glucose control. Adv Drug Deliv Rev 2004;
56:125–144
7. Bequette BW. A critical assessment of algo-
rithms and challenges in the development
of a closed-loop artiﬁcial pancreas. Diabetes
Technol Ther 2005;7:28–47
8. Hovorka R, Allen JM, Elleri D, et al.
Manual closed-loop insulin delivery in
children and adolescents with type 1 di-
abetes: a phase 2 randomised crossover
trial. Lancet 2010;375:743–751
9. Hovorka R, Kumareswaran K, Harris J,
et al. Overnight closed loop insulin delivery
(artiﬁcial pancreas) in adults with type 1
diabetes: crossover randomised controlled
studies. Br Med J 2011;342:d1855
10. Murphy HR, Elleri D, Allen JM, et al.
Closed-loop insulin delivery during preg-
nancy complicated by type 1 diabetes. Di-
abetes Care 2011;34:406–411
11. Murphy HR, Kumareswaran K, Elleri D,
et al. Safety and efﬁcacy of 24-h closed-
loop insulin delivery in well-controlled
pregnant women with type 1 diabetes:
a randomized crossover case series. Di-
abetes Care 2011;34:2527–2529
12. Weinzimer SA, Steil GM, Swan KL, Dziura
J, Kurtz N, Tamborlane WV. Fully auto-
mated closed-loop insulin delivery versus
semiautomated hybrid control in pediat-
ric patients with type 1 diabetes using an
artiﬁcial pancreas. Diabetes Care 2008;31:
934–939
13. Steil GM, Rebrin K, Darwin C, Hariri F,
SaadMF. Feasibility of automating insulin
delivery for the treatment of type 1 di-
abetes. Diabetes 2006;55:3344–3350
14. Brage S, Brage N, Franks PW, Ekelund U,
Wareham NJ. Reliability and validity of
the combined heart rate and movement
sensor Actiheart. Eur J Clin Nutr 2005;59:
561–570
15. Brage S, Brage N, Franks PW, et al.
Branched equation modeling of simulta-
neous accelerometry and heart rate mon-
itoring improves estimate of directly
measured physical activity energy expen-
diture. J Appl Physiol 2004;96:343–351
16. Brage S, Ekelund U, Brage N, et al. Hier-
archy of individual calibration levels for
heart rate and accelerometry to measure
physical activity. J Appl Physiol 2007;103:
682–692
17. Mazor E, AverbuchA, Bar-ShalomY,Dayan
J. Interacting multiple model methods in
target tracking: a survey. IEEETrans Aerosp
Electron Syst 1998;34:103–123
18. Kovatchev BP, Cox DJ, Gonder-Frederick
LA, Young-Hyman D, Schlundt D, Clarke
W. Assessment of risk for severe hypo-
glycemia among adults with IDDM: vali-
dation of the low blood glucose index.
Diabetes Care 1998;21:1870–1875
19. ClarkeWL. The original Clarke Error Grid
Analysis (EGA). Diabetes Technol Ther
2005;7:776–779
20. Wilson DM, Xing D, Beck RW, et al.;
Juvenile Diabetes Research Foundation
Continuous Glucose Monitoring Study
Group. Hemoglobin A1c and mean glu-
cose in patients with type 1 diabetes:
analysis of data from the Juvenile Diabetes
Research Foundation continuous glucose
monitoring randomized trial. Diabetes
Care 2011;34:540–544
21. Goodyear LJ, Kahn BB. Exercise, glucose
transport, and insulin sensitivity. Annu
Rev Med 1998;49:235–261
22. Peyrot M, Barnett AH, Meneghini LF,
Schumm-Draeger PM. Insulin adherence
behaviours and barriers in the multina-
tional Global Attitudes of Patients and
Physicians in Insulin Therapy study. Di-
abet Med 2012;29:682–689
23. Bailey T, Zisser H, Chang A. New features
and performance of a next-generation
SEVEN-day continuous glucose moni-
toring system with short lag time. Di-
abetes Technol Ther 2009;11:749–755
24. Wilinska ME, Chassin LJ, Acerini CL, Allen
JM, Dunger DB, Hovorka R. Simulation
environment to evaluate closed-loop in-
sulin delivery systems in type 1 diabetes.
J Diabetes Sci Tech 2010;4:132–144
25. Wilinska ME, Budiman ES, Taub MB, et al.
Overnight closed-loop insulin delivery with
model predictive control: assessment of
hypoglycemia and hyperglycemia risk us-
ing simulation studies. J Diabetes Sci Tech
2009;3:1109–1120
26. Steil GM, Palerm CC, Kurtz N, et al. The
effect of insulin feedback on closed loop
glucose control. J Clin Endocrinol Metab
2011;96:1402–1408
27. El-Khatib FH, Russell SJ, Nathan DM,
Sutherlin RG, Damiano ER. A bihormo-
nal closed-loop artiﬁcial pancreas for
type 1 diabetes. Sci Transl Med 2010;2:
27ra27
28. Castle JR, Engle JM, El Youssef J, Massoud
RG, Ward WK. Factors inﬂuencing the
effectiveness of glucagon for preventing
hypoglycemia. J Diabetes Sci Tech 2010;
4:1305–1310
29. Castle JR, Engle JM, El Youssef J, et al.
Novel use of glucagon in a closed-loop
system for prevention of hypoglycemia in
type 1 diabetes. Diabetes Care 2010;33:
1282–1287
30. Burdick J, Chase HP, Slover RH, et al.
Missed insulin meal boluses and elevated
hemoglobin A1c levels in children re-
ceiving insulin pump therapy. Pediatrics
2004;113:e221–e224
31. Pankowska E, Skórka A, Szypowska A,
Lipka M. Memory of insulin pumps and
their record as a source of information
about insulin therapy in children and
adolescents with type 1 diabetes. Diabetes
Technol Ther 2005;7:308–314
32. Tamborlane WV, Beck RW, Bode BW,
et al.; Juvenile Diabetes Research Founda-
tionContinuousGlucoseMonitoring Study
Group. Continuous glucose monitoring
and intensive treatment of type 1 diabetes.
N Engl J Med 2008;359:1464–1476
844 DIABETES CARE, VOLUME 36, APRIL 2013 care.diabetesjournals.org
Day-and-night closed loop in adolescents
